A Phase 2 interventional study of Lutetium [177Lu] oxodotreotide/dotatate in Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma and Paraganglioma, sponsored by Advanced Accelerator Applications. Active, not recruiting at 7 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Advanced Accelerator Applications (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Pheochromocytoma with a site in United States — 19 open to participants now, 28 under way, none of them phase 3. Pheochromocytoma · United States.
Among the 69 studies in Pheochromocytoma with a site in United States, this one is the 40th largest by enrollment of the 52 interventional ones that give a count, is the only one that started in 2022, is one of 30 in phase 2, reaches primary completion later than 0 of the 25 other live ones, and was the 56th registered.
158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.
Browse Pheochromocytoma studies →19 of the 69 studies in Pheochromocytoma with a site in United States are open now. Recruiting first, the newest first:
Anusha Kalbasi · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Pheochromocytoma studies recruiting now, 22 (51%) set no upper age limit and 6 (14%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 36 · Phase 3 3
First in 1988; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 37 across 87 interventional studies indexed under Pheochromocytoma.
Median enrollment 31 across the 52 interventional studies, 370 across the 10 observational. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Advanced Accelerator Applications, one of the names counted as Novartis. Under that name alone:
Advanced Accelerator Applications is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Novartis has 2 studies filed under Pheochromocytoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Pheochromocytoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05636540Heather WachtelIn Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | 2026-12-31 |
| NCT03839498Columbia UniversityStudy of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | 2027-01 |
| NCT03541720St. Jude Children's Research Hospital18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | 2027-01-01 |
| NCT03946527Antonio FojoLAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | 2027-03 |
| NCT00107289Memorial Sloan Kettering Cancer CenterIodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Pheochromocytoma with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
The study schedule for each patient consists of the screening period (up to 2 weeks) followed by the treatment period (4 treatment administrations at 8-week interval), and the follow-up period (10 years).
The treatment period will consist of 4 Lutathera treatments administered at 8-week intervals. Lutathera administration will occur on Week 1 Day 1 of each cycle. Each patient will receive a total of 4 doses of Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi). An infusion of 2.5% Lysine - Arginine amino acid (AA) solution will be co-administered with each Lutathera dose for renal protection according to the approved Lutathera local prescribing information. An antiemetic will be administered prior to infusion of the AA solution for prevention of infusion-related nausea and vomiting.
The dosimetry and PK assessments will be performed during the first week after the 1st Lutathera dose, i.e. one time during the study treatment period for each patient. The dosimetry analysis will allow for estimation from the 1st Lutathera administration of the cumulative absorbed radiation dose from 4 Lutathera doses and also for taking a decision on the next dose levels. In the exceptional circumstances when dosimetry cannot be performed in a particular patient after the first Lutathera dose, it should be completed as soon as feasible upon a later dose. In order to minimize risk for each study subject, an accelerated analysis of dosimetry and safety data will be performed for each patient in the study, to enable the Investigator to take a decision for the subsequent Lutathera doses. The results of dosimetry assessments (imaging and blood dosimetry) will be provided to the investigators for their evaluation prior to administration of subsequent therapeutic cycles in each patient.
A total follow-up period of 10 years (120 months) after the last Lutathera dose will take place for each patient who received at least one dose of Lutathera. This follow-up period will be comprised of a short-term follow-up of 6 months to evaluate cumulative Lutathera toxicities, followed by a long-term follow up of another 114 months.
An external Data and Safety Monitoring Board (DSMB) will also operate in the study to evaluate accumulating safety and dosimetry data, to ensure the safety of adolescents enrolled in the study, and to provide recommendations to investigators as well as to the clinical team in charge of conducting the study.
Key Inclusion Criteria:
GEP-NET cohort: presence of metastasized or locally advanced, inoperable (curative intent), proven, G1 or G2 (Ki-67 index =\< 20%), well differentiated GEP-NET.
or PPGL cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven PPGL.
Key Exclusion Criteria:
Laboratory parameters:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
Drug: Lutetium [177Lu] oxodotreotide/dotatate
Drug page: Lutetium-177
Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Also known as: Lutathera
Absorbed Radiation Doses in Target Organ
Absorbed radiation doses in target organ (e.g. kidney and bone marrow) was evaluated when all Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and Pheochromocytoma and paraganglioma (PPGLs) as a pooled cohort patients had completed the 1st treatment of Lutathera and completed the dosimetry assessment.
Time frame: Up to 8 days after the first Lutetium [Lu 177] dotatate dose
Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration
Safety in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities after the first Lutathera dose.
Time frame: during first cycle of Lutetium [Lu 177] dotatate treatment (Cycle = 56 days)
Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up
Cumulative safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was assessed through the incidence of adverse events (AEs) and laboratory toxicities until 6 months after the last Lutathera dose.
Time frame: From first Lutetium [Lu 177] dotatate dose to 6 months after last dose, approx. 12 months
Incidence of Adverse Events (AEs) During the Long Term Follow-up
Long-term safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities during the 5-year follow-up after the last Lutathera dose.
Time frame: Up to 5 years after the last Lutetium [Lu 177] dotatate dose
Calculated Probability of Exceeding the Kidney and Bone Marrow External Beam Radiation Therapy (EBRT) Threshold
A comparative assessment of dosimetry for organs at risk specifically kidneys and bone marrow, was performed between adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study to confirm the probability of exceeding 29 Gy (kidneys) \& 2 Gy (bone marrow) thresholds.
Time frame: After 4 cycles of 7.4 GBq/200 mCi; each cycle is 8+/-1 weeks
Pharmacokinetics (PK) Parameter: AUClast - Based on Blood Radioactivity Concentration Data
A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
Time frame: Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
Pharmacokinetics (PK) Parameter: Cmax - Based on Blood Radioactivity Concentration Data
A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
Time frame: Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
Pharmacokinetics (PK) Parameter: Tmax - Based on Blood Radioactivity Concentration Data
A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
Time frame: Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
At the data cut-off (DCO) date (12-Mar-2024) for this primary analysis 11 participants were enrolled across 7 centers.
| Milestone | GEP-NET | PPGL |
|---|---|---|
| Started | 4 | 7 |
| Ongoing treatment | 0 | 1 |
| Entered short term follow-up | 4 | 5 |
| Entered long term follow-up | 1 | 3 |
| Completed | 4 | 5 |
| Not completed | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Ongoing treatment | 0 | 1 |
Absorbed radiation doses in target organ (e.g. kidney and bone marrow) was evaluated when all Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and Pheochromocytoma and paraganglioma (PPGLs) as a pooled cohort patients had completed the 1st treatment of Lutathera and completed the dosimetry assessment.
| Gy/GBq | GEP-NET | PPGL |
|---|---|---|
| Kidney | 0.71 ± 0.25 | 0.82 ± 0.32 |
| Pituitary | 1.2 ± 0.43 | 1.0 ± 0.45 |
| Red Marrow (Blood) | 0.024 ± 0.0035 | 0.028 ± 0.0052 |
| Red Marrow (Image) | 0.043 ± 0.018 | 0.067 ± 0.028 |
| Spleen | 0.63 ± 0.39 | 0.82 ± 0.17 |
| Urinary Bladder Wall | 0.50 ± 0.034 | 0.59 ± 0.096 |
| Total Body | 0.040 ± 0.013 | 0.041 ± 0.0073 |
Safety in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities after the first Lutathera dose.
| Participants | GEP-NET | PPGL |
|---|---|---|
| Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration | 4 | 6 |
Cumulative safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was assessed through the incidence of adverse events (AEs) and laboratory toxicities until 6 months after the last Lutathera dose.
| Participants | GEP-NET | PPGL |
|---|---|---|
| AEs during Lutathera treatment | 4 | 7 |
| AEs during short-term follow-up | 1 | 3 |
Long-term safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities during the 5-year follow-up after the last Lutathera dose.
Results for this outcome have not been posted.
A comparative assessment of dosimetry for organs at risk specifically kidneys and bone marrow, was performed between adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study to confirm the probability of exceeding 29 Gy (kidneys) \& 2 Gy (bone marrow) thresholds.
| probability | GEP-NET and PPGL |
|---|---|
| Observed: Kidney (Probability (%) >29 Gy) | 20.0 |
| Observed: Bone Marrow (Probability (%) >2 Gy) | 0.0 |
A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
| ng.h/mL | GEP-NET and PPGL |
|---|---|
| Observed | 41 ± 24.15 |
| Predicted | 32.34 ± 10.43 |
A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
| ng/mL | GEP-NET and PPGL |
|---|---|
| Observed | 11.17 ± 33.04 |
| Predicted | 10.31 ± 5.22 |
A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
| hr | GEP-NET and PPGL |
|---|---|
| Observed | 0.58 (0.5 to 0.77) |
| Predicted | 0.5 (0.5 to 0.7) |
Collected over AEs & on-treatment deaths were collected from the first dose of study treatment up to data cut-off date of 12-Mar-2024, approx. 19 months from the FPFV.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GEP-NET | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| PPGL | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Total | 0/11 (0%) | 2/11 (18.2%) | 11/11 (100%) |
| Event | GEP-NET | PPGL | Total |
|---|---|---|---|
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/4 | 0/7 | 1/11 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/4 | 0/7 | 1/11 |
| Device related infectionInfections and infestations | 0/4 | 1/7 | 1/11 |
| Event | GEP-NET | PPGL | Total |
|---|---|---|---|
| HeadacheNervous system disorders | 2/4 | 4/7 | 6/11 |
| AnaemiaBlood and lymphatic system disorders | 2/4 | 2/7 | 4/11 |
| LymphopeniaBlood and lymphatic system disorders | 2/4 | 2/7 | 4/11 |
| Abdominal painGastrointestinal disorders | 2/4 | 1/7 | 3/11 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 1/7 | 3/11 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/4 | 1/7 | 3/11 |
| NauseaGastrointestinal disorders | 1/4 | 3/7 | 4/11 |
| Lymphocyte count decreasedInvestigations | 0/4 | 3/7 | 3/11 |
| NeutropeniaBlood and lymphatic system disorders | 1/4 | 2/7 | 3/11 |
| VomitingGastrointestinal disorders | 1/4 | 2/7 | 3/11 |
Full Analysis Set (FAS): The FAS included all participants that received at least one dose of Lutathera.
| Age, Continuous(years) | GEP-NET | PPGL | Total |
|---|---|---|---|
| Mean | 15.5 ± 0.58 | 14.9 ± 1.77 | 15.1 ± 1.45 |
| Sex: Female, Male(Participants) | GEP-NET | PPGL | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | GEP-NET | PPGL | Total |
|---|---|---|---|
| White | 2 | 3 | 5 |
| Black or African American | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Not Reported | 1 | 2 | 3 |
| Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Aug 2022 to primary completion in Mar 2024, 18 months.
Results were first posted in Nov 2024, 8 months after primary completion.
Of 28 phase 2 interventional studies under Pheochromocytoma, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 157. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutetium-177
Advanced Accelerator Applications →